Company Overview

We are a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) TM in oncology and inflammation. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMAR xT Tissue-Specific TM Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. We use systems biology principles for rapid candidate selection and effective pre-clinical studies, leading to efficient manufacturing/scale up processes, toxicology and IP, followed by selection of appropriate contract research organizations and high-speed enrollment clinical trial sites.

SEC Filings

Date

Form

Description

2021-09-17

S-1

General form for registration of securities under the Securities Act of 1933

2021-07-20

DRS

Draft Registration Statement

Press Releases

ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors Novel Approach Combining ImmixBio Tissue Specific Therapeutics (TSTx)™ with Immunotherapies Could Expand the Population Of Cancer Patients Experiencing Extended Remissions News provided byImmix Biopharma, Inc.Aug 27, 2021, […]
ImmixBio Announces Dr. Galit Lahav of Harvard Medical School Joins Scientific Advisory Board Dr. Galit Lahav, pioneer of understanding why individual human cancer cells often show different responses to the same treatment (including p53 and NF-kB signaling dynamics), and identifying new therapies that will increase the […]
ImmixBio Announces Dr. George W. Sledge of Stanford University Medical Center Joins Scientific Advisory Board Dr. George W. Sledge, former ASCO president, pioneering clinical investigator of multiple approved cancer therapeutics including multi-kinase inhibitor abemaciclib (marketed as VERZENIO® by Eli Lilly) and paclitaxel News provided byImmix Biopharma, […]

In The News

Oncology biotech Immix Biopharma files for a $25 million IPO Renaissance Capital September 17, 2021 Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, filed on Friday with the SEC to raise up to $25 million in an initial public offering. Immix is […]
Newsletters – Term Sheet – IPOs Fortune September 17, 2021 “Immix Biopharma, a Los Angeles-based oncology drug company, filed for an initial public offering …” Original Article Link
BeiGene and Immix ink collaboration agreement for IMX-110/tislelizumab cancer study Seeking Alpha Aug. 27, 2021 8:47 AM ET By: Aakash Babu, SA News Editor     BeiGene (NASDAQ:BGNE) and Immix Biopharma announce a clinical trial and supply agreement to evaluate the safety, tolerability and efficacy of a […]
Immix Biopharma submits registration statement for IPO Seeking Alpha Jul. 23, 2021 11:11 AM ET By: Jonathan M Block, SA News Editor Immix Biopharma has confidentially submitted a draft registration statement (S-1 form) for an initial public offering. The number of shares to be offered and […]
West LA-Based Biotech ImmixBio – Maker of Cancer Treatments – Files for an IPO dot.la Keerthi Vedantam 03:52 PM | July 23, 2021 ImmixBio, a West L.A.-based startup developing cancer therapies, announced on Friday it submitted a confidential filing to go public. Ilya Rachman, chief executive […]
FierceBiotech FireceBiotech Chutes & Ladders Jul 9, 2021 9:30am “Immix Bio, focused on tissue-specific therapeutics for oncology and inflammation, chose Gabriel Morris as its chief financial officer and board member.” Original Article Link